400 related articles for article (PubMed ID: 26600871)
1. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives.
Pavlovic D; Patera AC; Nyberg F; Gerber M; Liu M;
Ther Adv Neurol Disord; 2015 Nov; 8(6):255-73. PubMed ID: 26600871
[TBL] [Abstract][Full Text] [Related]
2. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
3. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
[TBL] [Abstract][Full Text] [Related]
4. Advances in the management of PML: focus on natalizumab.
Fox R
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
[TBL] [Abstract][Full Text] [Related]
5. Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice.
Carruthers RL; Berger J
Mult Scler Relat Disord; 2014 Jul; 3(4):419-30. PubMed ID: 25877052
[TBL] [Abstract][Full Text] [Related]
6. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.
Ferenczy MW; Marshall LJ; Nelson CD; Atwood WJ; Nath A; Khalili K; Major EO
Clin Microbiol Rev; 2012 Jul; 25(3):471-506. PubMed ID: 22763635
[TBL] [Abstract][Full Text] [Related]
7. Radiological abnormalities in progressive multifocal leukoencephalopathy: Identifying typical and atypical imaging patterns for early diagnosis and differential considerations.
Soni N; Ora M; Mangla R; Singh R; Ellika S; Agarwal A; Meyers SP; Bathla G
Mult Scler Relat Disord; 2023 Sep; 77():104830. PubMed ID: 37418930
[TBL] [Abstract][Full Text] [Related]
8. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review.
Sharma K; Tolaymat S; Yu H; Elkhooly M; Jaiswal S; Jena A; Kakara M; Sriwastava S
J Neurol Sci; 2022 Dec; 443():120459. PubMed ID: 36283150
[TBL] [Abstract][Full Text] [Related]
9. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration.
Dunham SR; Schmidt R; Clifford DB
Neurotherapeutics; 2020 Jul; 17(3):955-965. PubMed ID: 32166631
[TBL] [Abstract][Full Text] [Related]
11. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis.
Sahraian MA; Radue EW; Eshaghi A; Besliu S; Minagar A
Eur J Neurol; 2012 Aug; 19(8):1060-9. PubMed ID: 22136455
[TBL] [Abstract][Full Text] [Related]
12. Severe Progressive Multifocal Leukoencephalopathy (PML) and Spontaneous Immune Reconstitution Inflammatory Syndrome (IRIS) in an Immunocompetent Patient.
Krey L; Raab P; Sherzay R; Berding G; Stoll M; Stangel M; Wegner F
Front Immunol; 2019; 10():1188. PubMed ID: 31191548
[No Abstract] [Full Text] [Related]
13. Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.
Ishii K; Yamamoto F; Homma S; Okada Y; Nakamichi K; Saijo M; Tamaoka A
BMC Neurol; 2019 Oct; 19(1):263. PubMed ID: 31672142
[TBL] [Abstract][Full Text] [Related]
14. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS).
Bauer J; Gold R; Adams O; Lassmann H
Acta Neuropathol; 2015 Dec; 130(6):751-64. PubMed ID: 26323992
[TBL] [Abstract][Full Text] [Related]
15. Progressive multifocal leukoencephalopathy.
Weissert R
J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
[TBL] [Abstract][Full Text] [Related]
16. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
[TBL] [Abstract][Full Text] [Related]
19. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Rath L; Vijiaratnam N; Skibina O
Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
[TBL] [Abstract][Full Text] [Related]
20. Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy.
Sainz-de-la-Maza S; Casado JL; Pérez-Elías MJ; Moreno A; Quereda C; Moreno S; Corral I
Eur J Neurol; 2016 May; 23(5):919-25. PubMed ID: 26914970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
